Search

Under the title “Linking the ubiquitin family: physiology, disease and future directions”, SEBBM, together with the Fundación Carmen y Severo Ochoa, is organizing the second Severo Ochoa Conference on

The regional government of Castilla y León authorized Bioxytol to develop its projects in Árevalo, Ávila, after evaluating and considering that its development implies a minimum environmental impact.

Next-generation DNA sequencing has a significant impact on personalized medicine, genomic research, and the identification of genetic diseases.

The three companies, members of AseBio, work every day to improve treatments and patients' lives through rapid diagnosis of infectious diseases, intestinal microbiota, and precision oncology.

On the occasion of the International Day of the Laboratory Animal, we analyze the legislative and utilization situation of animal experimentation, essential for progress in fields such as oncology

Nitrite water pollution has been a pending issue in Spain for several years. The European Commission already warned about this problem in November 2018, and now, it has been condemned by the European

Quibim has held two webinars on the early detection of prostate cancer and the applications of artificial intelligence at clinical levels.

BCN HEALTH has published the study ‘Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study’ in the journal ‘Expert Review of Pharmacoeconomics & Outcomes

They receive a grant of half a million euros to prepare the clinical and commercial strategy for vaccination against Klebsiella pneumoniae and Acinetobacter baumannii bacteria.

We analyze the challenges and opportunities of the biotechnology sector in areas such as financing and driving its disruptive innovations, led by Antonio López, CEO of SILO, Silver Sponsor of the

Has received “Intention to Grant” from the European Patent Office.

According to the INE, when exclusively analyzing the figures in Companies, R&D investment has increased by 18% compared to 2021: 1.223 billion euros compared to 1.038 billion euros, respectively.

Meet Owkin, our new member. We talked to its Francisco Miguel Torres, Partnerships Director, Southern Europe.

Biotechnology has radically transformed the discovery of new drugs: 68% of the drugs currently in development globally are biotechnological.

Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating symptoms once the diagnosis has been made.

Meet Copal Scientific, our new member. We talked to its Mercedes Iriarte Cela, CEO.

Meet Spinally Medical, our new member. We talked to its Carles García-Vitoria, Co-fundador & Chief Scientific Officer.

In combination with either atezolizumab or durvalumab.

With the aim of analyzing the Spanish biotechnological ecosystem and delving into the challenges and opportunities it presents, we interviewed Susana de Antonio Horcajo, Head of Listing Spain at

Spinally Medical introduces FuturaLead™, a subarachnoid device for spinal cord stimulation aimed at patients suffering from chronic pain.